Pharmacological Treatment of Generalized Anxiety Disorder

First-Line Medications

• The American College of Cardiology is not applicable here, however, the guideline recommends selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) as first-line pharmacological treatments for Generalized Anxiety Disorder (GAD) due to their established efficacy and favorable safety profiles 1
• Paroxetine and fluvoxamine are effective SSRIs but may have more discontinuation symptoms 2
• Duloxetine (60-120 mg/day) has demonstrated efficacy in GAD and has additional benefits for patients with comorbid pain conditions 3
• Venlafaxine (75-225 mg/day) is effective for GAD but requires careful titration and monitoring for blood pressure increases 3, 2

Second-Line Medications

• Pregabalin/Gabapentin can be considered when first-line treatments are ineffective or not tolerated, and have shown efficacy in GAD, particularly for patients with comorbid pain conditions 3

Treatment Algorithm

• Initial treatment should start with an SSRI (preferably escitalopram or sertraline) or SNRI (duloxetine or venlafaxine), and begin with lower doses and titrate gradually to minimize side effects 1, 3
• Inadequate response to first medication trial should be addressed by switching to a different SSRI or SNRI, and considering adding cognitive behavioral therapy (CBT) if not already implemented 1, 4

Important Monitoring Considerations

• Assess response using standardized anxiety rating scales (e.g., HAM-A) 1
• Monitor for common side effects of SSRIs/SNRIs, including nausea, sexual dysfunction, headache, insomnia 3
• Monitor for duloxetine side effects, including nausea, which can be reduced by starting at 30 mg daily for one week 3
• Monitor for venlafaxine side effects, including blood pressure increases and discontinuation symptoms 3

Clinical Pitfalls to Avoid

• Tricyclic antidepressants (TCAs) should be avoided due to their unfavorable risk-benefit profile, particularly cardiac toxicity 3, 4

First-Line Medications for Anxiety

Efficacy and Response Timeline

• SSRIs as a class have demonstrated improvement in primary anxiety symptoms, response to treatment, and remission of disorder with moderate to high strength of evidence, according to the American Academy of Child and Adolescent Psychiatry 5
• The response to SSRIs typically follows a logarithmic model with statistically significant improvement within 2 weeks, clinically significant improvement by week 6, and maximal improvement by week 12 or later, as reported by the Journal of the American Academy of Child and Adolescent Psychiatry 5
• Common side effects of SSRIs/SNRIs include nausea, sexual dysfunction, headache, insomnia, dry mouth, diarrhea, heartburn, somnolence, dizziness, and vivid dreams, as noted by the Journal of the American Academy of Child and Adolescent Psychiatry 5
• Most adverse effects emerge within the first few weeks of treatment, as stated by the Journal of the American Academy of Child and Adolescent Psychiatry 5

Medication Options

• Fluoxetine and fluvoxamine are effective options for anxiety disorders, with fluoxetine having a longer half-life that may be beneficial for patients who occasionally miss doses, according to the Journal of the American Academy of Child and Adolescent Psychiatry 5

Medication for Anxiety and Rumination

First-Line Treatment: SSRIs

• The American Academy of Child and Adolescent Psychiatry recommends starting with a low dose of sertraline (25-50 mg daily) or escitalopram (5-10 mg daily) to minimize initial anxiety/agitation that can occur with SSRIs 6
• The American Academy of Child and Adolescent Psychiatry suggests titrating sertraline by 25-50 mg increments every 1-2 weeks as tolerated, and escitalopram by 5-10 mg increments, with target doses of sertraline 50-200 mg/day and escitalopram 10-20 mg/day 6

Alternative First-Line: SNRIs

• The American Academy of Child and Adolescent Psychiatry recommends venlafaxine extended-release 75-225 mg/day as an effective alternative, but requires blood pressure monitoring due to risk of sustained hypertension 7

Critical Warnings

• The American Academy of Child and Adolescent Psychiatry warns that paroxetine has a higher risk of discontinuation syndrome and potentially increased suicidal thinking compared to other SSRIs 6

Treatment Duration

• The American Academy of Child and Adolescent Psychiatry recommends discontinuing medication gradually to avoid withdrawal symptoms, particularly with shorter half-life SSRIs 6

If First SSRI Fails

• The American Academy of Child and Adolescent Psychiatry suggests switching to a different SSRI (e.g., sertraline to escitalopram or vice versa) after 8-12 weeks at therapeutic doses with inadequate response 6

Special Considerations for Rumination

• The American Academy of Child and Adolescent Psychiatry recommends combining medication with cognitive behavioral therapy (CBT) specifically targeting rumination patterns for optimal outcomes 6

Non-Controlled Medication Options for Anxiety

First-Line Pharmacotherapy: SSRIs and SNRIs

• The American College of Neuropsychopharmacology recommends escitalopram and sertraline as top-tier first-line agents due to their established efficacy, favorable side effect profiles, and lower risk of discontinuation symptoms compared to other SSRIs 8
• The Canadian guideline deprecates beta blockers (atenolol, propranolol) for social anxiety disorder based on negative evidence 8
• Paroxetine and fluvoxamine are equally effective but carry higher risks of discontinuation symptoms and should be reserved for when first-tier SSRIs fail 8
• Venlafaxine extended-release (75-225 mg/day) is effective for generalized anxiety disorder, social anxiety disorder, and panic disorder 8

Combination with Psychotherapy

• Combining medication with cognitive behavioral therapy targeting anxiety patterns provides optimal outcomes, with CBT having demonstrated efficacy comparable to or exceeding pharmacotherapy alone for anxiety disorders 8
• Individual CBT is prioritized over group therapy due to superior clinical and health-economic effectiveness 8

First-Line Treatment for Generalized Anxiety Disorder

Combination Therapy

• Individual cognitive behavioral therapy (CBT) is prioritized over group therapy due to superior clinical and cost-effectiveness, as recommended by the American Psychological Association, with large effect sizes for GAD (Hedges g = 1.01) 9

Treatment of Generalized Anxiety Disorder

Therapeutic Approach

• The American Academy of Child and Adolescent Psychiatry recommends cognitive-behavioral therapy (CBT) with specific elements, including education on anxiety, cognitive restructuring to challenge distortions, relaxation techniques, and gradual exposure when appropriate, for the treatment of generalized anxiety disorder (GAD) in adults, with a large effect size (Hedges g = 1.01) 10, 11
• A structured duration of 12-20 CBT sessions is recommended to achieve significant symptomatic and functional improvement in patients with GAD 11

Fluoxetine Titration Schedule for Anxiety Treatment

Initial Dosing and Titration Strategy

• The American Academy of Child and Adolescent Psychiatry recommends starting fluoxetine at 5-10 mg daily and increasing by 5-10 mg increments every 1-2 weeks, targeting a therapeutic dose of 20-40 mg daily by weeks 4-6, with maximal benefit expected by week 12, to minimize initial anxiety, agitation, or activation symptoms 12
• Most adverse effects, such as nausea, headache, insomnia, and nervousness, emerge within the first few weeks and typically resolve with continued treatment, highlighting the importance of gradual dose escalation 12
• The gradual up-titration prevents unintentionally exceeding the optimal dose, as SSRI response follows a logarithmic model with diminishing returns at higher doses, supporting the slow titration approach 12

Expected Timeline for Response and Monitoring

• Statistically significant improvement may begin by week 2, with clinically significant improvement expected by week 6, and maximal therapeutic benefit achieved by week 12 or later, providing a timeline for response evaluation 12
• Monitor closely for suicidal thinking and behavior, especially in the first months and following dose adjustments, with a pooled risk difference of 0.7% vs placebo, and a number needed to harm (NNH) of 143, emphasizing the need for careful monitoring 12

Treatment Duration and Adjustment

• Full response may take 12+ weeks, and treatment should not be abandoned prematurely, as patience in dose escalation is crucial for optimal outcomes 12
• Do not escalate doses too quickly, allowing 1-2 weeks between increases to assess tolerability and avoid overshooting the therapeutic window, to ensure safe and effective treatment 12

Social Anxiety Disorder Treatment Guidelines

Guideline-Recommended Treatment

• The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology recommends selective serotonin reuptake inhibitors (SSRIs) as the first-line pharmacological treatment for social anxiety disorder, with a weak recommendation and low certainty evidence (GRADE 2C) 13, 14
• The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology suggests venlafaxine (SNRI) as an alternative treatment for social anxiety disorder, with a weak recommendation and low certainty evidence (GRADE 2C) 13, 14
• Cognitive behavioral therapy (CBT) specifically developed for social anxiety disorder, such as the Clark and Wells model or Heimberg model, is recommended through individual sessions 13, 14

Clinical Algorithm for Social Anxiety Disorder

• The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology recommends referring patients for individual CBT specifically designed for social anxiety disorder, in conjunction with first-line pharmacological treatment 13, 14

Anxiety Disorder Management

Non-Pharmacological Interventions

• The American Academy of Child and Adolescent Psychiatry recommends providing psychoeducation to family members about anxiety symptoms and treatment, as well as considering referral for treatment for parents or caregivers who struggle with anxiety themselves 15
• Breathing techniques, progressive muscle relaxation, grounding strategies, visualization, distraction, thought reframing, and mindfulness are useful adjunctive anxiety management strategies, according to the Journal of Neurology, Neurosurgery and Psychiatry 16
• Regular cardiovascular exercise and activities of enjoyment are also recommended as adjunctive anxiety management strategies 16
• Sensory grounding techniques, such as noticing environmental details and cognitive distractions, can help prevent dissociation 16

First-Line Treatment of Anxiety

Introduction to First-Line Treatment Options

• The American College of Physicians recommends Cognitive Behavioral Therapy (CBT) as the first-line treatment for anxiety disorders, with SSRIs (escitalopram or sertraline) or SNRIs (venlafaxine or duloxetine) as the first-line pharmacological options when psychotherapy is unavailable, not preferred by the patient, or when combined treatment is needed 17

Pharmacotherapy

• The American College of Physicians suggests starting with an SSRI or SNRI when medication is indicated, with venlafaxine extended-release 75-225 mg/day being effective for generalized anxiety disorder, panic disorder, and social anxiety disorder, requiring blood pressure monitoring 17

Adjunctive Non-Pharmacological Interventions

• The American Society of Clinical Oncology recommends structured physical activity and exercise as adjunctive treatment, providing moderate to large reduction in anxiety symptoms 18
• Exercise is beneficial alongside primary treatment, with breathing techniques, progressive muscle relaxation, grounding strategies, and mindfulness being useful adjunctive strategies 18, 19

Combined Treatment Approach

• Combining medication with CBT provides superior outcomes, according to the American College of Physicians 17

Best First-Line Medication for Anxiety and Panic Attacks

Introduction to SSRIs

• SSRIs demonstrate high-quality evidence for efficacy in anxiety and panic disorders with moderate to high strength of evidence, showing improvement in primary anxiety symptoms, response to treatment, and remission rates, as recommended by the American Academy of Child and Adolescent Psychiatry 20

Expected Timeline for Response

• Patients should understand that SSRI response follows a logarithmic pattern, with statistically significant improvement beginning at week 2, clinically significant improvement expected at week 6, and maximal therapeutic benefit achieved at week 12 or later, according to the American Academy of Child and Adolescent Psychiatry 20

Common Side Effects to Monitor

• Most adverse effects emerge within the first few weeks and typically resolve with continued treatment, including nausea, diarrhea, dry mouth, heartburn, headache, dizziness, somnolence or insomnia, sexual dysfunction, nervousness, and tremor, as reported by the American Academy of Child and Adolescent Psychiatry 20
• Critical warning: All SSRIs carry a boxed warning for suicidal thinking and behavior, with pooled absolute rates of 1% versus 0.2% for placebo, and close monitoring is essential, especially in the first months and following dose adjustments, as warned by the American Academy of Child and Adolescent Psychiatry 20

Second-Line Treatment Options

• If inadequate response after 8-12 weeks at therapeutic doses, consider switching to a different SSRI or adding cognitive behavioral therapy, and SNRIs such as venlafaxine or duloxetine may be considered as second-line treatment, as suggested by the American Academy of Child and Adolescent Psychiatry 21

Medications to Avoid

• Benzodiazepines should be reserved for short-term use only due to risks of dependence, tolerance, and withdrawal, as cautioned by the American Academy of Family Physicians 22

Combination Treatment Consideration

• For patients with severe anxiety or panic disorder, combination treatment with SSRI and CBT provides superior outcomes compared to either treatment alone, with moderate strength of evidence, as found by the American Academy of Child and Adolescent Psychiatry 21

Plan of Care for New Onset Anxiety in an 18-Year-Old

Initial Assessment and Diagnosis

• The American Academy of Child and Adolescent Psychiatry recommends initiating treatment with either cognitive behavioral therapy (CBT) or a selective serotonin reuptake inhibitor (SSRI), with sertraline or escitalopram as the preferred first-line medications for an 18-year-old with new onset anxiety 23
• Anxiety must persist for at least 6 months to meet diagnostic criteria for generalized anxiety disorder, social anxiety disorder, or other primary anxiety disorders, according to the Neuropsychopharmacology guidelines 24
• It is essential to rule out substance-induced anxiety and ensure symptoms are not caused by drugs of abuse, pharmaceuticals, or other medical conditions, as stated in the Neuropsychopharmacology guidelines 24
• Approximately one-third of anxiety patients have comorbid conditions, such as depression, substance use, and other psychiatric disorders, which should be screened for, as recommended by the Neuropsychopharmacology guidelines 24

First-Line Treatment Options

• The American Academy of Child and Adolescent Psychiatry suggests that CBT is equally effective as first-line treatment and should be offered based on patient preference and availability 23
• Combination treatment (CBT + SSRI) provides superior outcomes compared to either treatment alone for patients with moderate to severe anxiety, supported by moderate strength of evidence from the Child-Adolescent Anxiety Multimodal Study (CAMS) 23

Medications to Avoid

• The BMJ guidelines recommend avoiding benzodiazepines as first-line treatment due to risks of dependence, tolerance, and withdrawal, and reserving them only for short-term use 25

Alternative Treatment for Anxiety After Lexapro Failure

Introduction to Alternative Treatments

• The American Academy of Neuropsychopharmacology recommends switching immediately to another SSRI, such as sertraline 25-50 mg daily or paroxetine 10 mg daily, or an SNRI, such as venlafaxine XR 75 mg daily, as bupropion lacks efficacy for anxiety and may worsen symptoms 26, 27
• The American Academy of Family Physicians states that bupropion is contraindicated for anxiety disorders because it is activating and can exacerbate anxiety symptoms, agitation, and nervousness 28

Recommended Medication Options

• The American Academy of Neuropsychopharmacology suggests that paroxetine can be started at 10 mg daily, titrated to 40 mg/day, though higher discontinuation symptoms than sertraline may occur 26, 27, 29
• The American Academy of Neuropsychopharmacology recommends that fluvoxamine can be started at 50 mg twice daily, titrated to 150 mg twice daily 26, 27
• The American Academy of Neuropsychopharmacology advises that venlafaxine XR can be started at 75 mg daily, titrated to 75-225 mg/day, requiring blood pressure monitoring 26, 27

SSRI Efficacy and Recommendations for Anxiety Disorders

Primary Recommendations

• The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guidelines (2023) suggest fluvoxamine, paroxetine, and escitalopram as first-choice medications for social anxiety disorder, with sertraline noted as equally effective 30, 31
• All SSRIs as a class demonstrate similar efficacy with NNT = 4.70 for treatment response in social anxiety disorder, meaning approximately 1 in 5 patients will respond to SSRIs who would not have responded to placebo 30, 32
• SNRIs (venlafaxine 75-225 mg/day or duloxetine 60-120 mg/day) can be considered as second-line treatment if inadequate response after 8-12 weeks at therapeutic doses of SSRIs 30, 32

Combination Therapy

• Combining medication with CBT provides superior outcomes compared to either treatment alone, particularly for moderate to severe anxiety 33

Treatment Strategies for Generalized Anxiety Disorder

Monitoring and Treatment Duration

• The American College of Physicians recommends continuing effective medication for a minimum of 9-12 months after achieving remission to prevent relapse, with reassessment monthly until symptoms stabilize, then every 3 months 34, 35
• The American Psychiatric Association suggests monitoring for treatment adherence, side effects, and functional improvement using standardized scales, such as the GAD-7 or HAM-A, and altering treatment strategy if no improvement after 8 weeks at therapeutic doses despite good adherence 34, 35

Critical Clinical Considerations

• Patients with anxiety pathology commonly avoid follow-through on referrals, so it is essential to proactively assess and address barriers to treatment adherence, as recommended by the National Institute of Mental Health 34, 35

Switching from Sertraline for Panic Disorder

Efficacy and Switching Strategies

• The American Academy of Child and Adolescent Psychiatry recommends that all SSRIs demonstrate comparable efficacy for panic disorder with moderate to high strength of evidence, showing improvement in panic symptoms, treatment response, and remission rates 36
• Individual SSRIs vary in their pharmacokinetic profiles, side effect patterns, and drug interaction potential, making switching within the class a rational first step before moving to different medication classes, as suggested by the American Academy of Child and Adolescent Psychiatry 37, 36
• Escitalopram has the least effect on CYP450 isoenzymes compared to other SSRIs, resulting in lower propensity for drug interactions, according to the American Academy of Child and Adolescent Psychiatry 37
• Escitalopram has a lower risk of discontinuation syndrome compared to sertraline, paroxetine, and fluvoxamine, as reported by the American Academy of Child and Adolescent Psychiatry 37
• Fluvoxamine is effective for panic disorder but has greater potential for drug-drug interactions through multiple CYP450 pathways, and a higher risk of discontinuation syndrome similar to paroxetine, as noted by the American Academy of Child and Adolescent Psychiatry 37
• The American Academy of Child and Adolescent Psychiatry suggests tapering sertraline gradually to avoid discontinuation syndrome, and cross-tapering by reducing sertraline by 25-50 mg every 1-2 weeks while simultaneously starting the new SSRI at a low dose 37
• The American Academy of Child and Adolescent Psychiatry recommends starting the new SSRI at a subtherapeutic "test" dose to minimize initial anxiety or agitation that can occur with SSRIs 37
• Combination treatment (SSRI + cognitive behavioral therapy) provides superior outcomes compared to medication alone for panic disorder with moderate strength of evidence, as suggested by the American Academy of Child and Adolescent Psychiatry 36

Medication for Performance-Limited Social Anxiety

Understanding Performance-Limited Social Anxiety

• Performance-limited social anxiety is a subtype where the fear is limited to speaking or performing an action in public, differing from generalized social anxiety disorder which involves persistent fear across multiple social situations lasting 6 months or more 38, 39, 40, 41

Evidence-Based Treatment Approach

For Chronic Performance Anxiety

• The American Psychiatric Association recommends escitalopram, paroxetine, or fluvoxamine as first-line pharmacotherapy for social anxiety disorder, including the performance-limited subtype 38, 42, 43

For Acute Performance Situations

• Beta-blockers, such as propranolol, are deprecated by Canadian guidelines for chronic social anxiety disorder treatment, but may be used for acute performance anxiety in musicians and public speakers, though this represents off-label use with limited controlled evidence 43

Recommended Clinical Algorithm

• If performance anxiety occurs only occasionally and does not cause significant functional impairment, consider as-needed strategies, according to the American Psychiatric Association 38, 39
• If anxiety is recurrent, persistent, or causes significant distress/impairment, treat as chronic social anxiety disorder, as recommended by the American Psychiatric Association 38, 39, 40

Combination Therapy Considerations

• Combining medication with individual cognitive behavioral therapy (CBT) provides superior outcomes for patients with moderate to severe performance anxiety, compared to either treatment alone, as suggested by the American Psychiatric Association 42, 43

Management of Anxiety

Initial Assessment and Treatment

• Medical causes such as hyperthyroidism, caffeinism, hypoglycemia, asthma exacerbations, cardiac arrhythmias, and other endocrine disorders should be ruled out before initiating treatment, as recommended by the American Academy of Child and Adolescent Psychiatry 44
• Structured physical activity/exercise provides a moderate to large reduction in anxiety symptoms, according to the Journal of Clinical Oncology 45
• Avoid excessive caffeine and alcohol as both can exacerbate anxiety symptoms, as noted by the American Academy of Child and Adolescent Psychiatry 44
• Sleep hygiene education can address insomnia which commonly co-occurs with anxiety, as recommended by the Journal of Clinical Oncology 45
• Breathing techniques, progressive muscle relaxation, and mindfulness are useful adjuncts to primary treatment, according to the Journal of Clinical Oncology 45

Adjunctive Non-Pharmacological Strategies

• Gradual exposure to feared situations is an essential component of cognitive behavioral therapy (CBT) for anxiety, as recommended by the American Academy of Child and Adolescent Psychiatry 44
• The American Academy of Child and Adolescent Psychiatry recommends CBT as a first-line treatment for anxiety, with a recommended duration of 12-20 sessions for significant symptomatic and functional improvement 44

Quetiapine Use in Anxiety: Lack of FDA Approval and Polypharmacy Concerns

Regulatory Status

• Quetiapine is not FDA‑approved for the treatment of anxiety disorders and lacks guideline endorsement as a primary pharmacologic option for these conditions【46】.

Polypharmacy Risks

• In a young adult patient already receiving an atypical antipsychotic, a benzodiazepine, a beta‑blocker, and a mood stabilizer, adding quetiapine would create unnecessary polypharmacy, which guideline statements explicitly advise avoiding due to increased risk of metabolic disturbances and sedation【46】【47】.

Guideline for Managing Mild Anxiety (GAD‑7 5‑9) and Minimal Depression (PHQ‑9 ≤3)

Initial Assessment

• Assess functional impairment by using the functional‑impairment item of the GAD‑7 questionnaire, which asks how anxiety interferes with work, home responsibilities, and social interactions. 48
• Evaluate functional impairment with the same GAD‑7 item to identify patients whose mild symptom scores mask significant daily‑life disruption. 49

Criteria for Initiating Pharmacotherapy

• Consider pharmacologic treatment when anxiety symptoms persist for more than 8 weeks despite adequate non‑pharmacologic therapy (e.g., CBT, lifestyle measures). 48
• Initiate medication if the GAD‑7 score rises to ≥10, indicating progression to moderate‑severity anxiety. 50
• Start pharmacotherapy when the functional‑impairment assessment reveals substantial interference with daily activities, even if symptom scores remain mild. 51
• Offer medication if the patient, after a shared‑decision discussion of risks and benefits, prefers pharmacologic options. 52

Monitoring and Treatment Adjustment

• If no clinically meaningful improvement is observed after 8 weeks of an adequately dosed and adhered‑to regimen, modify the treatment plan by adding or switching interventions. 49
• Regularly reassess anxiety and depressive symptoms using standardized scales (GAD‑7, PHQ‑9) to detect the need for treatment changes. 49

Clinical Pitfalls to Avoid

• Do not commence pharmacotherapy for mild anxiety before trialing evidence‑based non‑pharmacologic interventions such as CBT, which provide more durable benefits. 48
• Do not overlook the functional‑impairment assessment; significant impairment may justify earlier or more intensive treatment despite low symptom scores. 51

All statements are supported by citations from the Journal of Clinical Oncology as indicated.

Second‑Tier SSRIs for Panic Disorder in Young Adults

Alternative First‑Line SSRIs (Second‑Tier Options)

• Paroxetine and fluvoxamine show efficacy comparable to other SSRIs but are recommended as second‑tier agents for panic disorder in young adults due to higher rates of discontinuation symptoms and greater potential for drug‑drug interactions. 53

Evidence‑Based Alternatives and Nausea Management for Anxiety Medication Switch

Venlafaxine XR as an Effective Alternative

• Venlafaxine extended‑release 75–225 mg daily demonstrates efficacy for generalized anxiety disorder, social anxiety disorder, and panic disorder, offering a mechanistically distinct option when a switch within the SSRI class is undesirable. 54

Risks Associated with Paroxetine and Fluvoxamine

• Paroxetine and fluvoxamine provide comparable efficacy to other SSRIs but are linked to a higher incidence of discontinuation symptoms; therefore, they should be reserved for cases where first‑tier SSRIs have failed. 54

Strategies for Persistent Nausea

• If nausea persists beyond 2–3 weeks after initiating a new anxiolytic, add a proton‑pump inhibitor or H₂‑blocker to address possible gastritis/reflux, and reassess for non‑medication causes. 55
• Short‑term use of dopamine‑receptor antagonists (e.g., metoclopramide, prochlorperazine) can alleviate ongoing nausea, but long‑term therapy should be avoided because of the risk of extrapyramidal side effects. 55

Drug Interaction Considerations for Propranolol

Interaction with Sleep‑Related Medications

• Trazodone, commonly prescribed for sleep, shows minimal pharmacokinetic or pharmacodynamic interaction with propranolol, indicating it can generally be co‑administered without dose adjustment. [56][57]

Interaction with Alcohol‑Use‑Disorder Medications

• Naltrexone, used to support alcohol abstinence, does not have significant pharmacokinetic interactions with propranolol, allowing concurrent use when clinically indicated. [58][59]

Interaction with Neuropathic‑Pain/Adjunct Medications

• Gabapentin, when given as a short course, may produce additive sedative effects when combined with propranolol; clinicians should monitor patients for excessive sedation or dizziness and adjust therapy as needed. [56][57]

Risks of Combining Multiple CNS Depressants

• Co‑administration of propranolol with other central nervous system depressants such as trazodone and gabapentin can increase the likelihood of additive sedation and orthostatic hypotension, warranting careful monitoring of sedation levels and blood pressure. 57